IL299256A - Cerebellum binding compounds, their compounds and methods of treatment with them - Google Patents
Cerebellum binding compounds, their compounds and methods of treatment with themInfo
- Publication number
- IL299256A IL299256A IL299256A IL29925622A IL299256A IL 299256 A IL299256 A IL 299256A IL 299256 A IL299256 A IL 299256A IL 29925622 A IL29925622 A IL 29925622A IL 299256 A IL299256 A IL 299256A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- compound
- unsubstituted
- substituted
- halogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043555P | 2020-06-24 | 2020-06-24 | |
| PCT/US2021/038618 WO2021262810A1 (en) | 2020-06-24 | 2021-06-23 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299256A true IL299256A (en) | 2023-02-01 |
Family
ID=79032408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299256A IL299256A (en) | 2020-06-24 | 2021-06-23 | Cerebellum binding compounds, their compounds and methods of treatment with them |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11634407B2 (enExample) |
| EP (1) | EP4171566A4 (enExample) |
| JP (2) | JP7781792B2 (enExample) |
| CN (2) | CN120441548A (enExample) |
| AR (1) | AR122723A1 (enExample) |
| AU (1) | AU2021296833A1 (enExample) |
| BR (1) | BR112022025933A2 (enExample) |
| CA (1) | CA3182325A1 (enExample) |
| CL (1) | CL2022003719A1 (enExample) |
| CO (1) | CO2022018653A2 (enExample) |
| IL (1) | IL299256A (enExample) |
| MX (1) | MX2022015757A (enExample) |
| PE (1) | PE20231746A1 (enExample) |
| SA (1) | SA522441857B1 (enExample) |
| TW (1) | TWI924678B (enExample) |
| WO (1) | WO2021262810A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| IL299256A (en) | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
| ES3047718T3 (en) | 2020-06-24 | 2025-12-04 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| KR20240026939A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2020051260A1 (en) | 2018-09-05 | 2020-03-12 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| BR112021011968A2 (pt) | 2018-12-19 | 2021-09-08 | Celgene Corporation | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos |
| AU2019404022A1 (en) | 2018-12-19 | 2021-07-08 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| IL299256A (en) * | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
| ES3047718T3 (en) | 2020-06-24 | 2025-12-04 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
-
2021
- 2021-06-23 IL IL299256A patent/IL299256A/en unknown
- 2021-06-23 BR BR112022025933A patent/BR112022025933A2/pt unknown
- 2021-06-23 US US17/356,370 patent/US11634407B2/en active Active
- 2021-06-23 WO PCT/US2021/038618 patent/WO2021262810A1/en not_active Ceased
- 2021-06-23 PE PE2022003029A patent/PE20231746A1/es unknown
- 2021-06-23 MX MX2022015757A patent/MX2022015757A/es unknown
- 2021-06-23 CN CN202510574007.2A patent/CN120441548A/zh active Pending
- 2021-06-23 CA CA3182325A patent/CA3182325A1/en active Pending
- 2021-06-23 AR ARP210101735A patent/AR122723A1/es unknown
- 2021-06-23 CN CN202180044295.0A patent/CN115835866B/zh active Active
- 2021-06-23 JP JP2022580090A patent/JP7781792B2/ja active Active
- 2021-06-23 AU AU2021296833A patent/AU2021296833A1/en active Pending
- 2021-06-23 TW TW110122923A patent/TWI924678B/zh active
- 2021-06-23 EP EP21827824.0A patent/EP4171566A4/en active Pending
-
2022
- 2022-12-22 SA SA522441857A patent/SA522441857B1/ar unknown
- 2022-12-22 CO CONC2022/0018653A patent/CO2022018653A2/es unknown
- 2022-12-22 CL CL2022003719A patent/CL2022003719A1/es unknown
-
2023
- 2023-03-16 US US18/122,496 patent/US12103920B2/en active Active
-
2024
- 2024-07-18 US US18/776,606 patent/US20250188056A1/en active Pending
-
2025
- 2025-11-26 JP JP2025203650A patent/JP2026035702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11634407B2 (en) | 2023-04-25 |
| KR20230027066A (ko) | 2023-02-27 |
| CO2022018653A2 (es) | 2023-03-27 |
| MX2022015757A (es) | 2023-01-19 |
| JP2023533203A (ja) | 2023-08-02 |
| JP2026035702A (ja) | 2026-03-04 |
| CA3182325A1 (en) | 2021-12-30 |
| SA522441857B1 (ar) | 2024-07-21 |
| BR112022025933A2 (pt) | 2023-01-10 |
| EP4171566A1 (en) | 2023-05-03 |
| WO2021262810A1 (en) | 2021-12-30 |
| TW202216680A (zh) | 2022-05-01 |
| PE20231746A1 (es) | 2023-11-06 |
| US20210403454A1 (en) | 2021-12-30 |
| CL2022003719A1 (es) | 2023-05-12 |
| US20250188056A1 (en) | 2025-06-12 |
| JP7781792B2 (ja) | 2025-12-08 |
| EP4171566A4 (en) | 2024-07-24 |
| CN120441548A (zh) | 2025-08-08 |
| AR122723A1 (es) | 2022-09-28 |
| CN115835866B (zh) | 2025-05-02 |
| US20230242509A1 (en) | 2023-08-03 |
| CN115835866A (zh) | 2023-03-21 |
| AU2021296833A1 (en) | 2023-01-19 |
| TWI924678B (zh) | 2026-05-11 |
| US12103920B2 (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| IL292753B1 (en) | Compounds, and compositions containing them, and their uses in the treatment of psychiatric or neurological disorders | |
| IL268030B2 (en) | Bicyclics as allosteric shp2 inhibitors | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| JP2016106141A (ja) | ｃ−Ｍｅｔモジュレーターの使用方法 | |
| CN108368090A (zh) | 作为免疫调节剂的化合物 | |
| JP2019529444A5 (enExample) | ||
| AU2014323812B2 (en) | Thienopiperidine derivative and use thereof | |
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| MX2024003738A (es) | Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico. | |
| MX2022014192A (es) | Metodos para tratar el cancer de prostata. | |
| JP2019529460A5 (enExample) | ||
| WO2023158679A3 (en) | Thiostrepton-inspired compounds for treatment of cancer and preparation thereof | |
| JP2023531495A5 (enExample) | ||
| JP2020531463A5 (enExample) | ||
| MX2023004937A (es) | Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas. | |
| JP2019512515A5 (enExample) | ||
| JP2024546851A5 (enExample) | ||
| CN109956986A (zh) | 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用 | |
| CN111303178A (zh) | Ovatodiolide衍生物及其盐，制备方法及其在制备抗癌药物中的用途 | |
| IL291570B2 (en) | Pharmaceutical preparations | |
| CN115397815A (zh) | 稠合二环类衍生物、其制备方法及其在医药上的应用 | |
| RU2011126173A (ru) | Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триаза-тетрацикло [19.3.1.1 (2,6).1(8,12)]гептакоза-1-( 25),2( 26),3,5,8,10,12( 27),16,21,23-декаена | |
| CN108473507A (zh) | 噻吩并嘧啶化合物的结晶形式 | |
| RU2019123589A (ru) | Производные оксазола для применения при лечении рака |